Valuation : Alzinova AB

Market Cap 171M 17.99M 15.45M 14.46M 13.24M 24.94M 1.72B 25.01M 66.94M 866M 67.56M 66.1M 2.87B P/E 2026 *
-3.13x
P/E 2027 * -2.22x
Enterprise Value 155M 16.31M 14M 13.11M 12M 22.61M 1.56B 22.68M 60.68M 785M 61.24M 59.92M 2.6B EV / Sales 2026 *
4.95x
EV / Sales 2027 * -
Free-Float
75.07%
Yield 2026 *
-
Yield 2027 * -
1 day-0.59%
1 week+2.56%
Current month-27.59%
1 month-18.45%
3 months+96.95%
6 months+36.59%
Current year+1.33%
1 week 0.77
Extreme 0.766
0.9
1 month 0.75
Extreme 0.751
1.23
Current year 0.38
Extreme 0.382
1.61
1 year 0.38
Extreme 0.382
2.28
3 years 0.38
Extreme 0.382
4.62
5 years 0.38
Extreme 0.382
8.7
10 years 0.38
Extreme 0.382
44.9
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2024
Chief Operating Officer 54 17/08/2011
Director of Finance/CFO 57 27/03/2024
Director TitleAgeSince
Director/Board Member 61 01/09/2015
Director/Board Member 69 01/01/2018
Director/Board Member - 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
-0.59%+2.56%-39.31%-74.85% 17.99M
-0.78%-1.42%+2.49%+22.78% 51.14B
-6.87%-0.71%+442.67%+544.70% 47.4B
-0.18%+0.76%+38.72%+18.04% 43.19B
-1.99%-2.16%+22.96%+81.30% 42.35B
-0.31%-1.75%+17.23%+52.37% 33.23B
-0.55%-2.39%+28.11%+131.57% 17.07B
-0.95%-1.78% - - 16.38B
-0.88%-0.66%+11.60%+27.75% 14.76B
-1.04%-0.76%+79.48%+47.39% 14.15B
Average -1.42%+0.94%+67.11%+94.56% 27.97B
Weighted average by Cap. -1.84%+1.12%+99.13%+137.75%

Financials

2026 *2027 *
Net sales 31.35M 3.29M 2.83M 2.65M 2.42M 4.57M 315M 4.58M 12.26M 159M 12.37M 12.1M 525M -
Net income -4.45M -468K -401K -376K -344K -648K -44.66M -650K -1.74M -22.51M -1.76M -1.72M -74.49M -77M -8.09M -6.95M -6.5M -5.95M -11.22M -773M -11.25M -30.1M -389M -30.38M -29.72M -1.29B
Net Debt -16M -1.68M -1.44M -1.35M -1.24M -2.33M -161M -2.34M -6.25M -80.93M -6.31M -6.18M -268M -19M -2M -1.71M -1.6M -1.47M -2.77M -191M -2.78M -7.43M -96.1M -7.5M -7.33M -318M
Logo Alzinova AB
Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric Aβ that damages brain synapses.
Employees
7
Date Price Change Volume
29/08/26 SEK 0.8400 -0.59% 1,676,168
27/08/26 SEK 0.8450 +1.32% 887,200
26/08/26 SEK 0.8340 -1.18% 914,405
25/08/26 SEK 0.8440 +5.11% 1,317,058
24/08/26 SEK 0.8030 -1.95% 1,937,472

Annual profits - Rate of surprise